ALX Oncology (NASDAQ:ALXO) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

ALX Oncology (NASDAQ:ALXO) released its quarterly earnings data on Friday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04), Zacks reports.

Here are the key takeaways from ALX Oncology’s conference call:

• Evorpacept (EVO)
• The Phase 2 ASPEN‑09‑Breast trial has been expanded from 80 to up to 120 patients and the primary endpoint was refocused to response rate in CD47‑high patients, with top‑line data for the 80‑patient cohort expected in mid‑2027 and a companion diagnostic in development.
• ALX2004 (EGFR‑targeted ADC) is in dose escalation (now dosing 4 mg/kg after clearing 1 and 2 mg/kg cohorts); company expects full dose‑escalation safety data in H2 2026 and highlights preclinical signals of potent activity with limited ILD/skin toxicity in NHP studies.
• ALX completed an equity financing (gross $150M; net ~$140.4M) and says cash on hand now supports operations through the first half of 2028, strengthening the balance sheet to fund near‑term catalysts across both programs.
• Q4 GAAP net loss narrowed to $22.8M from $29.2M a year earlier and management says spending will be concentrated on EVO and ALX2004 while legacy trials wind down, reducing some near‑term spend but concentrating program risk on two assets.

ALX Oncology Price Performance

ALXO traded down $0.24 on Friday, reaching $2.11. The company had a trading volume of 1,020,473 shares, compared to its average volume of 697,137. ALX Oncology has a 52-week low of $0.40 and a 52-week high of $2.66. The company has a market cap of $114.40 million, a price-to-earnings ratio of -1.04 and a beta of 0.51. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.40 and a current ratio of 2.40. The business has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $1.49.

Wall Street Analyst Weigh In

ALXO has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on ALX Oncology in a research report on Thursday, November 13th. They set a “buy” rating and a $4.00 price target on the stock. Piper Sandler upped their target price on shares of ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $2.50.

Insider Activity at ALX Oncology

In related news, Director Corey S. Goodman purchased 3,184,713 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were purchased at an average price of $1.57 per share, with a total value of $4,999,999.41. Following the acquisition, the director directly owned 8,453,038 shares of the company’s stock, valued at approximately $13,271,269.66. This represents a 60.45% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 21.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. purchased a new stake in ALX Oncology during the third quarter valued at about $1,195,000. Renaissance Technologies LLC increased its position in shares of ALX Oncology by 157.2% during the 4th quarter. Renaissance Technologies LLC now owns 423,099 shares of the company’s stock valued at $478,000 after purchasing an additional 258,600 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ALX Oncology during the 2nd quarter valued at about $84,000. Acadian Asset Management LLC lifted its position in ALX Oncology by 16.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after buying an additional 186,883 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in ALX Oncology by 26.9% in the third quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock worth $1,110,000 after buying an additional 128,737 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.

Featured Stories

• Five stocks we like better than ALX Oncology
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• This makes me furious
• Buy this Gold Stock Before May 2026
• What a Former CIA Agent Knows About the Coming Collapse